Pacira BioSciences Appoints Chris Christie to Board of Directors
PARSIPPANY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced the appointment of Christopher J. Christie to its board of directors.
PARSIPPANY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced the appointment of Christopher J. Christie to its board of directors. Chris Christie served as the 55th Governor of the State of New Jersey from January 2010 to January 2018.
“We are honored to welcome Governor Christie to the Pacira board of directors. Governor Christie’s track record of unwavering commitment to combatting our nation’s opioid crisis and his solid reputation as a seasoned government leader is unparalleled. He is distinguished for effecting bipartisan change within healthcare policy and legislation, and his insights should prove to be of immeasurable benefit to Pacira,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “We are delighted to have Governor Christie join the Pacira team and look forward to what we expect will be many contributions to advancing our mission to provide opioid-sparing alternatives to patients worldwide.”
During two successful terms as Governor of New Jersey, Christie significantly raised public consciousness around the acceleration of opioid and other drug-related deaths. His administration mandated new approaches to address the stigma around drug addiction and focused on making treatments more broadly available. He significantly expanded drug courts and executed landmark bipartisan legislation that placed new restrictions on opioid prescriptions leading to the most restrictive policy in the nation. His strong track record as Governor of New Jersey led President Trump to appoint him as Chairman of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. Governor Christie led this bipartisan group through multiple hearings, site visits, and interviews that informed 56 distinct recommendations for Congress, federal agencies, and local governments to fund and implement. In parallel, Christie’s administration successfully stimulated the New Jersey economy, created jobs, reformed education, reduced the size and cost of government, and lowered taxes for the state’s citizens.
Prior to serving as Governor of New Jersey, Christie served as United States Attorney for the District of New Jersey, where he earned national attention for his success in battling political corruption, corporate crime, human trafficking, gangs, terrorism, and environmental polluters.
Governor Christie received a Bachelor of Arts degree in Political Science from the University of Delaware, and a Juris Doctor degree from Seton Hall University School of Law. Christie is a recipient of Honorary Doctoral degrees from Rutgers University, University of Delaware, Seton Hall University, Monmouth University, and Centenary College.
About Pacira BioSciences
Pacira BioSciences, Inc. (Nasdaq: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera° system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Forward-Looking Statements
Any statements in this press release about Pacira’s future expectations, plans, outlook and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the company’s ability to successfully transition and integrate Mr. Reinhardt into the company as president; the company’s ability to realize the anticipated benefits and synergies from the acquisition of MyoScience, Inc. (“MyoScience”); the ability to successfully integrate iovera° and MyoScience into Pacira’s existing business; the commercial success of iovera°, the success of the company’s sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and the company’s ability to serve those markets; the company’s plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; and other factors discussed in the “Risk Factors” of the company’s most recent Annual Report on Form 10-K and in other filings that the company periodically makes with the SEC. In addition, the forward-looking statements included in this press release represent the company’s views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such the company anticipates that subsequent events and developments will cause its views to change. However, while the company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.
Investor Contact: Susan Mesco, (973) 451-4030 [email protected] Media Contact: Coyne Public Relations Alyssa Schneider, (973) 588-2270 [email protected]
